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This knowledge-based acuv1ty is targeted for all pharmacists and is
acceptable for 1.0 hour (0. 1 CEU) of continuing education credit This
course requires completion of the program evaluation and at least a
70 percent grade on the program assessment questions.
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CPE Universal Activity Number (UAN)' 0048-0000-11-001-H01-P

Objectives:
After compleoon of this program, the reader should be able to
1. Describe the vanables that account for differences m response to
clopldogrel therapy and which accounts for the most vanation m
response.
2. List the clinical effects or complications that may result from a
decreased paoont response to clopidogrel.
3. Explain the vanous tesong methods available to detect a va.riaoon
that can result m decreased clopidogrel response.
4. Describe the vanous advanrages and disadvantages of the currently available tesong met.hods.
5. Discuss what constitutes a i:oor metabolizer and the risks associated with this phenotype
6. Explain the pha.rmacisrs role m advocating for and providing access to genetc tesong

Abstract
Clop1dogrel, the top prescnbed 3nllplatelet med1cat1on for 1nd1v1duals who have experienced a myocardial infarction or cerebral
vascular accident or who have peripheral arterial disease, 1s
administered orally as a prodrug. It relies on hepatic metabolism
through cytochrome P450 enzy11es for conversion to its active
form. Current research shows that allelic variation m the gene
coding for CYP2C19 is the main factor contributing to the variability
of response associated with clop1dogrel treatment. Through the
promotion of geneoc testing forvanability in the CYP2C19 gene
and competently interpreting rest results, pharmacists have the
opportunity to use these findings to significantly impact clopidogrel
p<escnb1ng and dosing By tailoring an 1nd1v1dual's dosing regimen
pharmacists can maximize the efficacy of clopldogrel for a paoent
according to his or her genotype

Introduction
Over the last 11 years, physicians have presc'ibed clopidogrel (Plavix0)
to more than 100 million people. 1 Clopidogrel s commonly used to
prevent thrombotic events in patients who have recently experienced
a myocardial infarction (Ml) or cerebral vasculu accident (CVA) and in
those who have established peripheral artena disease (PAD). Given
that clop1dogrel 1s an orally administered prodrug, ltS efficacy is dependent on its b1oact1vat1on via hepatic metabolism. Cytochrome P450
enzymes, especially CYP2C 19, are essential 'or the conversion to its
acove form. 2 Consequently, any vanab1hty In CYP2C19 can significanHy
impact the b1oact1vat1on of clopidogrel, thereby mfluencmg ltS efficacy.
As a result, the approved Plav1x~ product labeling caunons prescnbers
that reduced effectiveness 1s seen 1n paoents with impaired CYP2C19
function
Black Box Warning
In March 2010, the United States Food and Drug Administration (FDA)
added a black box warning to the cloptdogrel ebehng to alert health care
professionals that the drug may be less effecove in a certain population of pabents who are unable to convert 1t to the active form.3 The
black box warning states. "Clopldogrel hydrog~n sulfate effectiveness
is dependent on 1ts acovat1on to an acave met3bolite by CYP2C 19. In
paoenrs who are CYP2C 19 poor metabOlizers, c10ptdogre1 ar recommended doses forms less of that metabolrte a'ld has a smaller effect on
platelet funcoon. Compared with normal metabol1zers, poor CYP2C 19
metabohzers with acute coronary syndrome or undergoing percutaneous
coronary intervention treated with clop1dogrel at recommended doses
exhibit higher cardiovascular event rates. Tests are available to Identify
a patient's CYP2C 19 genotype; these tests can help determine therapeutic strategy. Consider alternative treatmem or treatment strategies m
CYP2C 19 poor metabolizers." By encouraging the use of genetic tests,
pharmacists can help in identifying patients who are poor metabolizers
of clop1dogrel, thus promoting the personaliza1ion and improved efficacy
of clopldogrel therapy.
Normal Clopidogrel Metabolism
Platelet aggregation 1s a normal response to tissue inpry; adenosine
d1phosphate (ADP) released from platelets ac:ivates neighboring platelets by binding to the P2Y 12 receptor, thus promoong platelet aggregation.• The acove form of clopidogrel inhibits this platelet aggregation by
1rrevers1bty binding the P2Y 12 receptor and 1nh1bmng the full actlVation of
the glycoprotem llblllla adhesion recepcors on platelets (Figure 1).
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the CYP2C19 gene. ·2, '3, '4, '5 and '17 .4-'~ The most common variants
are the first four, while the CYP2C19'17 vanant 1s associated w11t1 the
ultra-rapid metabolizer phenotype.

ss•.. co lnxri'"e

Clopidogrel Resistance Due to Genetic Variants
Three main factors have been identified that contnbute to the overall
1eliista11ce ur cluµi<.Jugrel uisµlayetJ i11 su111e patients; U1elie include diflerences in gastrointestinal (GI) absorption, platelet receptor abnormalities,
and variations in hepatic metabolism.4 The GI absorption of clopidogrel
is dependent on two main features the activity of GI esterases and P-gp
efflux pumps. Polymorphisms in the genes that code for P-gp efflux
pumps have been associated with an increase in the GI efflux of clopidogrel.9 Platelet receptor abnormalities, or polymorphisms in the genes
coding for the glycoprotein lib/Illa or the P2Y, 2 receptor, can cause
decreased metabolite binding and subsequem decreases tn platelet
aggregation.
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Figure 1. BioaclivabOn of clopidogrel via CYP450 system with CYP2C19
being the predominant activation pathway. Conversion of clop1dogrel
to the actJve moiety results in its mechanism of action as an inhibitor of
adenosine d1phosphate (ADP) induced platelet aggregation.
Following absorpbon from the small intestine, clopidogrel requires
several in vivo activation stef'.ll for conversion to its active form (Figure
1). 4 Some of the absorbed drug 1s excreted back into the 1ntestme via
P-glycoprotein(P-gp)-mediated efflux pumps , thereby decreasing the
amount of prodrug available for activation. Only about 15 percent of
the orally administered dose of clcpidogrel is metabolized by the GYP
system in the liver to yield the active metabolite, while the remaining
85 percent is hydrolyzed to an inactive form by esterases in the blood
(Figure 1).5 The CYP2C19 enzyme in the liver has been identified as
one of the most significant enzymes in regard to clopidogrel resistance.
Several classifications exist pertaining to an individual's genotype for
the CYP2C 19 enzyme; to be considered a normal metabolizer, also
referred to as an extensive metabolizer (EM), an individual must have no
genetic d1spanties in the gene that codes for CYP2C 19 and express the
wild type allele (CYP2C19'1 )4$·7•14 An intermediate metabollzer (IM) IS a
person with one "loss of function" allele, while a poor metabolizer (PM)
has two "loss of funct10n" alleles. 6 Intermediate and poor metabolizers
will have a decreased activity of cbpidogrel due to a decrease m the
formation of the acbve compound.14 There are five common mutations in
9
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The factor with the greatest impact on the resistance to clopidogrel
1s the genetic variations in the CYP isoenzyme pathways of hepatic
metabollsm.4The polymorphism identified to have the most significant
impact IS that of the CYP2C 19 gene. It is estimated that 33-50 percent
of the population has a variant form of the CYP2C 19 gene.' Full funcbon
of this gene, associated with the w11dtype'1allele, 1s required mboth
steps of clopidogrel metabolism: first for conversion of clopidogrel to
2-oxo-clopidogrel, and then for metabolism of 2-oxo-clopidogrel to the
active compound (Figure 1). 2•10 Many studies have linked variations in
CYP2C 19 to an increased risk of death or non-fatal Ml or CVA as well as
a greater occurrence of in-stent thromboses. TRITON-TIMI 38 investigators (ClinicalTrials.gov Identifier No. NCT00097591) identified that carriers of the CYP2C 19'2 allele had a significantly increased risk of death
from CV events, non-fatal Ml and CVA (p=.01Jand were three limes
more likely to experience an in-stent thrombosis (P=.02). 11 The FAST-Ml
studies linked genetic variation in the gene coding for the given enzyme,
especially the ·2 allele, to significantly increase the nsk of death, stroke,
Ml, revasculanzat1on and 1n-stent thrombosis. expression of any two of
the vanants associated with loss of function, r.art1eularty the ·2. '3, '4 , or
'5 alleles, nearly doubled the nsk of death or nonfatal Ml or stroke w1th1n
one year (p=.045).9 The PRING Trial demonstrated that 1f Identified,
1nd1viduals with genotypes indicative of poor response to clopldogrel,
particularly those expressing the '2 or '4 alleles, could experience
an increased degree of platelet inhibition if their dosing was modified
from what is currently considered to be the standard dose.12 The study
showed that while wildtype carriers had better platelet inhibition two
hours after a 600 mg loading dose compared ;o inhibition in ·2 and •4
individuals (p=.026), individuals with the '2 and '4 alleles had greater
inhibition than wildtype individuals with a 1,200 mg loading dose at four
hours (P=.002). Additionally, '2 and '4 individuals responded betterthan
w11dtype individuals with a 150 mg maintenance dose compared to the
standard 75 mg maintenance dose (p=.042).
By taking into account an individual's age, BMI, lipid levels and
CYP2C 19 genotype, approximately 22 percent of !tie vanatJOn of
clop1dogrel response can be explained.13 This leads to the conclusion
that assessment of the CYP2C 19 genotype may prove to be a useful
chnical tool for helping health care providers choose the most efficacious
antiplatelel U1erapy and dOliing regimen for a given patient.
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Non-genetic Testing
Phenotypmg can be performed to categorize the functional aspect of a
particular drug metabollzmg enzyme.14 This is not a genetic test. rather,
it involves !he patient consuming a probe drug that utilizes the enzyme
pathway of interest Measurements are made using the probe drug and
an inactive metabolite, and these measurements are then converted into

Pharmacogenomics

Advantages and Disadvantages of Genetic Testing
The costs of different genetic tes ts vary depending on the test and lab
being used but generally range trom $250 to $500.20 These tests may be
covered by a pat1en!'s insurance plan, though many insurance companies consider them to be "investigational, experimental or unproven."6
Due to evidence that genetic variations in the CYP2C19 gene are asso-

Cl rC1tio U1at serves i:IS U1e "rnelal.Jolic 11:1lio." Tl1is ri:ilio is use<.J Lo deter-

c1C1te<.J wiU1111creC1se<.J risks ror L11e occune11ce or adve1se ca1d10vasculC1r

mine the metabolic rate that allows an individual to be characterized as
an EM, PM or IM. These probe tests can be performed using a single
probe, or a "cocktail" of several probe drugs can be utilized to assess
multiple enzyme pathways concurrently. Before a "cocktail" is used, it
must be detenmined that no drug interactions exist between any of the
probes used to avoid confounding the resultant metabolic ratios.

events and in-stent thromboses, using pharmacogenomics and genetic
testing with clopidogrel therapy presents a real opportunity to decrease
health care costs despite the added costs of the testing itself. The use
of genetic tests can help the clinician identify and prevent situations in
which patients undergo clopidogrel treatment 1hat is rendered ineffective due to their genetic makeup. However, these tests also may identify
the need for a treatment that is likely to be more effective but also more
costly. The clinical application of this technology also has some drawbacks, including the invasive nature of these genetic tests, which require
blood to be drawn. Moreover, including a genetic test before prescribing
clopidogrel to a patient will increase turn-around time for a patient to
receive ltle appropriate anti-platelet therapy.

The phenotyp1c categones can be used to quantify how a patJent will
metabolize a drug ublizing that certain enzyme.14 The effect of being a
PM depends on whether the drug in question is pharmacologically active
or a prodrug. In lhe case of clopidogrel, a PM will experience a decrease
in the bioava1lab1hty of the active form of the drug. Phenotyping may be
difficult to perform cllnically because the measurements are not taken
until a number of hours after drug administration, therefore making th IS
type of testing more swtable for a research setting.14
An additional testing option is the proprietary VerifyNow-P2Y12 test, a
point-of-care assay that was developed by Accumetrics. 15 A small blood
sample is taken, and an ADP agonist is used to stimulate platelet aggregation. The test then measures hew well platelet aggregation is impaired
by clopidogrel. Thrombin receptoragonists are also used to approximate
the patienrs baseline platelet aggregation. 5
Genetic Testing
Molecular genetic testing entails examining the gene or genes that
code for an enzyme to see which alleles are present. There are several
generic tests available 10 investigate how well an individual will metabolize clop1dogrel. Two available tests are AmpliCl1ip™, developed by
Roche Diagnosucs, and Quest Diagnostic's AccuType™ CP. 1618 These
two genetic tests involve taking a patient's blood sample and testing
for variants in the CYP2C 19 genes using polymerase chain reactions
(PCRs), which is a method to make many copies of the genes so it can
be more easily measured. A computer program then analyzes the PCR
data and determines the genotype and corresponding phenotype of the
patient 16.11
The AmpliChip™ test is designed to be able to have the results available
in an eight-hour period.19 However, the time it takes for a patient's blood
to be drawn and tested and the results to be returned varies depending on the lab and test used. In order for these genetic tes ts to become
more clinically useful in clopidogrel therapy, technology must be developed to make test results available prior to dosing. Research currently
is being done on a technology that involves the use of a fluorescencebased assay that measures an energy exchange to distinguish the
target DNA sequence that codes for the specific enzyme.19 The goal rs to
develop a portable, low-cost and real-time assaying platform that could
potentially be used for on-site genetic testing.

Using genetic tests to determine if a patient has any polymorph1Sms in
the gene for CYP2C 19 may aid in individualizing and opt1m1zing clop1dogrel treatment 12 In a study done at the Sinai Hospital in Baltimore, Md.,
those with the CYP2C 19'2 gene mutation demonstrated no difference
in baseline platelet aggregation compared to those without the "loss
of function" allele. 13 However, those with the mutation demonstrated
greater residual platelet aggregation after clopidogrel therapy. After one
year of follow-up, those with the CYP2C19'2 genotype had higher rates
of cardiovascular events compared to those without the mutation. This
demonstrates the advantages of using genetic testing in conj:mction with
clopidogrel therapy.
Conclusion
Pharmac1Sts can play a key role in increasing awareness and access1b1hty of genetic testing, especially 1n the area of clopldogrel prescnbmg
and dosing. It 1s the responsibility of pharmac1Sts to ensure that patients
understand the benefits of these genetic tests In con.11mc11on with
pharmacist-run anti-coagulation cl1n1cs, on-site genetlC testing and subsequent clopidogrel dosing by a pharmacist could become a standard
made available to patients. Pharmacists, in both community and hospital
settings, may recommend to a prescriber an increased dose of clopidogrel or a change in therapy to an entirely different med1cation for patients
who have been deemed PMs according to results of their genetic testing. Using data presented in the PRING trial, phanmacists can advocate
for patients who are classified as PMs of clopdogrel, based on their
genotype concerning the CYP2C19 gene, tote treated with higher loading and maintenance doses. This will allow them to see platelet inhibition
comparable to outcomes observed with the standard dosing in EMs.
Such recommendations could consequently improve clinical outcomes
for patients who would otherwise see no benefit from this pharmaceutical therapy; however, patients can only beneftt from ltlis type of intervenllOn 1f their genotype can be quant1f1ed via genetic testing for vanants in
the CYP2C19 gene. The application of these geneoc test results rs an
area of practice that pharmacists can embrace as part of the movement
toward increased patient counseling and medication therapy managernent. The use or genetic testing in tile prescription a11d dosing or
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clopidogrel presents an opportunity for pharmacists in most practice settings to expand the degree of care provided to patients by encouraging
the personahzatlon of clopldogrel therapy. Rather than adhering to the
current "one size fits air' method of prescribing, pharmacists have the
opportunity to take a more proactive approach to customize antiplatelet
therapy based on a pallent's mdiv1dual needs and significantly increase
lfie elficacy or palient 11e1:1L111ent w1U1 clupic.J uyrel.
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8. Which are ways that pharmacists can be involved in genetic testing
and ctopldogre t dosing?
a. Ensure that patients are aware of testing avallab1hty and
benefits.
b. Provide clinics or on-site genetic testing for patlents.
c. Recommend a change in dosage or therapy if indicated by test

Assessment Questions
1. Which of the following are utilized mgenetic testing?
a. AmpltCh1pr"'
b. AccuType™
c. VenfyNow-P2Y12
d. A and 8

re:; ult:;.

2. AmpliChip™ uses _ _ to determine genotype.
a. Probe drug
b. PCR
c. ADP agonist
d. None of the above

d. All of the above

3. Which factor has been identified to contribute the most to variation in
response to clopidogrel therapy?
a. Variations m the CYP2C 19 enzyme
b. Platelet receptor abnorm3lities
c. Activity of GI esterases
d. Activity of P-gp efflux pumps
4. What 1s released from platelets during a normal response to tissue
inJury?
a.PLC
b. ATP
c. ADP
d. cAMP
5. What percentage of a normal orally administered dose of clopidogrel
is metabolized in the liver to the active form?
a. 85 percent
b. 50 percent
c. 25 percent
d. 15 percent

9. According to the PRING study, which options are available to optimize
therapy for poor metabolize rs of clopidogrel?
a. Longer course of therapy
b. Higher loading and maintenance doses
c. Recommend switching to a different therapy
d. Band C
10. All of the following are benefits of genetic testing EXCEPT.
a. Prevention of futile therapy
b. Rapid time frame to achieving appropnate clopidogrel therapy
c. Decreased overall health care costs
d. Decreased clinical complicat10ns
To receive continuing education credit for this program, you must
answer the above questions and fill out the evaluation form. Please visit
www.onu.edu/pharmacy--- to enter the required information. Please
allow two to three weeks for electronic distribution of your continuing
education certificate, which will be sent to your valid e-mail address in
PDF format.
Ohio Northern University is accredited bf the Accreditation
Council for Pharmacy Educat10n as a provider of continuing

pharmacy education. This program is eligitie for credit until
Jan. 1B, 2014.

6. An md!Vldual with two "toss of function" alleles 1s charactenzed as
which type of metaboltzer?
a. Extensive metabolizer
b. Intermediate metabolizer
c. Poor metabohzer
d. Normal metabolizer
7. According to the conclusions of the TRITON-TIMI study, all of the following are true for carriers of the CYP2C 19*2 variant EXCEPT:
a. Decreased risk of in-stent thrombosis
b. Increased risk of death from cardiovascular events
c. Increased risk of non-fatal Ml or CVA
d. Two of the above
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The program objectives were clear.
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Describe the variables that account for differences in response to clopidogrel therapy
and which accollllts for the most variation in response.

1

2

3

4

5

List the clinical effects or complications that can result in a decreased patient response
to clopidogrel.

1

2

3

4

5

Explain the various testing methods available to detect a variation that can result in
decreased clopidogrel response.

1

2

3

4

5

Describe the various advantages and disadvantages to die testing mediods currendy available. 1

2

3

4

5

Discuss what constitutes a poor metabolizer and what are the risks associated with this
phenotype.

1

2

3

4

5

Explain the pharmacist's role i11 advocating for and providing access to genetic testing.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program met the stated goals & objectives;
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9.A B C D
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